Grove Biopharma, Inc. | $30,000,000 | (Apr 25, 2025)
Northwood | $30,000,000 | (Apr 25, 2025)
Steadily Insurance Company | $30,000,000 | (Apr 25, 2025)
Certified by Founder
Lodge
RheumaGen
start up
United States
- Denver, Colorado
- 10/01/2025
- Series A
- $15,000,000
RheumaGen is a private biotechnology company engineering a new class of therapeutics to cure major autoimmune diseases at their source. RheumaGen focuses on editing the human leukocyte antigen (HLA), or “immune gene,” to develop one-time, curative cell and gene therapies. RheumaGen is headquartered in Aurora, Colorado. For more information, please visit rheumagen.com.
- Industry Biotechnology Research
- Website https://www.rheumagen.com/
- LinkedIn https://www.linkedin.com/company/rheumagen/
Alternative Payments | $22,000,000 | (Apr 25, 2025)
Listen Labs | $27,000,000 | (Apr 25, 2025)
Lace | $14,000,000 | (Apr 25, 2025)
RISE® Robotics | $1,500,000 | (Apr 25, 2025)
Ravenna | $15,000,000 | (Apr 25, 2025)
ChEmpower Corporation | $18,700,000 | (Apr 25, 2025)
Theo | $20,000,000 | (Apr 25, 2025)
Isembard | $9,000,000 | (Apr 25, 2025)
Electra(US) | $186,000,000 | (Apr 25, 2025)